Selective A2B Adenosine Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current A2B adenosine receptor antagonists lack selectivity, leading to side effects such as central nervous system stimulation, gastric secretion, diuresis, and arrhythmias, and interfere with the potential roles of A1 and A3 receptors in heart protection and tumor prevention.
Innovation Solution
Development of novel imidazopyridinone derivatives that are potent and selective antagonists of the A2B adenosine receptor, avoiding interference with A1 and A3 receptors, through a multi-step synthetic process involving halogenation, nitration, Suzuki-type coupling, and reduction, to produce compounds with specific fluorine and chlorine substitutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current A2B adenosine receptor antagonists are used, then they can block the A2B receptor, but they lack selectivity and cause side effects such as central nervous system stimulation, gastric secretion, diuresis, and arrhythmias
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (fluorine, chlorine, bromine, or trifluoromethyl at position 3 of the pyridin-4-yl group) to achieve selective binding to the A2B receptor subtype. This localized chemical modification enhances affinity and selectivity for A2B while avoiding activation of other adenosine receptor subtypes, thereby reducing side effects associated with non-selective blockade
2Adaptability or versatility
If A1 and A3 receptors are blocked along with A2B, then broader receptor coverage is achieved, but interference with heart protection and tumor prevention roles occurs
Solution Approach 1:
The patent extracts the A2B receptor blockade function from the broader non-selective adenosine receptor blockade. By designing compounds that specifically target A2B through the imidazopyridinone core structure with specific pyridin-4-yl substitutions, the invention isolates the therapeutic effect to A2B antagonism while preserving the protective functions of A1 and A3 receptors in heart protection and tumor prevention
3Reliability
If non-selective adenosine receptor antagonists are used, then multiple receptor subtypes are blocked, but side effects and loss of protective functions increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of the imidazopyridinone core, specifically the substitution patterns on the pyridin-4-yl group (positions 3, 4, or 5 with fluorine, chlorine, bromine, or trifluoromethyl). These structural parameter changes result in differential binding affinity across adenosine receptor subtypes, achieving high A2B selectivity with Ki values in the nanomolar range while minimizing interaction with A1, A2A, and A3 receptors
Data Source
AI summary
A compound of formula (I) wherein: G1 is selected from the groups consisting of fluorine and chlorine atoms, G2 is selected from the groups consisting of hydrogen, fluorine and chlorine atoms, and G3 is selected from the groups consisting of fluorine and chlorine atoms and pharmaceutically acceptable salts or N-oxides thereof.